3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
3
Leukemia
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Adenocarcinoma
1
Interventions
Temozolomide
154
Bevacizumab
88
Radiotherapy
75
Radiation
23
Magnetic Resonance Spectroscopy
23
Lomustine
18
Irinotecan
18
pembrolizumab
17
Surgical Procedures, Operative
16
Carmustine
16
Erlotinib Hydrochloride
12
Nivolumab
11
Specimen Handling
10
Aminolevulinic Acid
10
sargramostim
9
Thalidomide
9
Chemotherapy, Adjuvant
9
Carboplatin
9
Immunoglobulin G
7
Filgrastim
7
Etoposide
7
Drug Therapy
7
Disulfides
7
Cilengitide
7
Sunitinib
6
Sorafenib
6
O(6)-benzylguanine
6
Cyclophosphamide
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioblastoma
×
Valacyclovir
×
Clear all
NCT00589875
2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2
Completed
52 enrolled
10 charts